– FDA approval for a second-generation female condom, considered to be a boost in the fight against HIV in developing nations
– Congratulations to AIDS Walk New York and Gay Men’s Health Crisis for raising a record-breaking amount of corporate sponsorship for this year’s annual event.
– Gilead Sciences, a leader in HIV research and medical therapies, has purchased CV Therapeutics, which develops small-molecule drugs used to treat cardiovascular diseases. About Gilead and CV:
“Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
“CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Europe Ltd. is the company’s European subsidiary based in the United Kingdom.” —CV Therapeutics
– In Uganda, the Ministry of Health has announced an initiative to place nearly 50,000 more people on anti-retroviral therapy. The Ministry:
recommended that anti-retroviral (ARV) treatment should start when the CD4 count of adults is less than 250, instead of 200 as has been the case, Sam Zaramba, the director-general of Health Services, said in a statement.
-Until There’s A Cure